DCTH
Delcath Systems, Inc.
DCTH's fundamentals are strong: revenue grew 38% and it turned 18% of its revenue into free cash flow, though its operating margin fell 2 points to 5.2%. At 134x earnings, it's trading below its usual 166x. Analysts expect earnings to recover and profitability to improve.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DCTH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
DCTH's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DCTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 117x | $18.66 | -13% |
| Current | 134x | $21.38 | — |
| Fair | 166x | $26.50 | +24% |
| Forward | 1,071x | $21.38 | — |
| Expensive | 1,435x | $230 | +974% |
Historical ranges are pointers, not guarantees.
DCTH's PE is in its cheap range at 134x. On analysts' estimates for next year's earnings, today's price would be 1071x, in its fair range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DCTH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
DCTH has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DCTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | -88% |
| Q3 2026 | $0.16 | +167% |
| Q2 2026 | $0.01 | -90% |
| Q1 2026 | $0.01 | +$0.46 |
| Q4 2025 | $0.07 | +$1.00 |
| Q3 2025 | $0.06 | +$1.38 |
| Q2 2025 | $0.10 | +$2.62 |
| Q1 2025 | -$0.45 | +$2.17 |
| Q4 2024 | -$0.93 | +$2.01 |
DCTH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DCTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +71% |
| Q2 2026 | $29.1M | +21% |
| Q1 2026 | $25M | +26% |
| Q4 2025 | $20.7M | +37% |
| Q3 2025 | $20.6M | +84% |
| Q2 2025 | $24.2M | +211% |
| Q1 2025 | $19.8M | +530% |
| Q4 2024 | $15.1M | +2701% |
DCTH has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +22 points |
| Q2 2026 | 8.2% | -2.5 points |
| Q1 2026 | -6.5% | -9.8 points |
| Q4 2025 | -11% | -31 points |
| Q3 2025 | -1.9% | +9.3 points |
| Q2 2025 | 11% | +61 points |
| Q1 2025 | 3.3% | +331 points |
| Q4 2024 | 20% | +2117 points |
DCTH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DCTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +60% |
| Q2 2026 | $5.2M | -24% |
| Q1 2026 | $287K | -86% |
| Q4 2025 | $7.7M | +$8.9M |
| Q3 2025 | $4.3M | +$8.2M |
| Q2 2025 | $6.9M | +$11.4M |
| Q1 2025 | $2.1M | +$11.7M |
| Q4 2024 | -$1.2M | +$7M |
DCTH has burned cash in most quarters: $20M over the past year, up 67% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DCTH on cash flow, with more consistent year-over-year improvement.
DCTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +1.3M shares |
| 1 year | +2.4% | +963K shares |
| 3 years | +229% | +28.6M shares |
| 5 years | +514% | +34.3M shares |
DCTH has 41M diluted shares, up 2.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $11,000 |
| Q1 2026 | $3M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DCTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DCTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -9.0x | Net Cash |
| Q4 2025 | -44.2x | Net Cash |
| Q3 2025 | -6.8x | Net Cash |
| Q2 2025 | -6.5x | Net Cash |
DCTH has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DCTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.6 | Overbought |
| Stochastic | 60.2 | Neutral |
DCTH's weekly RSI is 77 (overbought) and its Stochastic is 60 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DCTH PE vs Healthcare Sector
| Metric | DCTH | Sector median | Relative |
|---|---|---|---|
| PE | 134x | 26x | 417% above |
| PE % | 26 | 29 | 3 pts below |
DCTH is trading at 134x earnings, a 417% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DCTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.6 | 37% above |
| 20 week MA | $15.1 | 41% above |
| 50 week MA | $12.2 | 75% above |
| 100 week MA | $12.3 | 73% above |
| 200 week MA | $9.19 | 133% above |
DCTH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DCTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.0 | $17.1 | -29% |
| 2021 | $17.1 | $8.45 | -51% |
| 2022 | $8.45 | $3.59 | -58% |
| 2023 | $3.59 | $4.16 | +16% |
| 2024 | $4.16 | $12.0 | +188% |
| 2025 | $12.0 | $10.3 | -14% |
| 2026 YTD | $10.3 | $21.4 | +108% |
DCTH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.